Intellectual disability - microarray and sequencing
Gene: NXF5 Red List (low evidence)Comment on list classification: Maintaining Red rating as evidence linking this gene to ID is not definitive since patient variants have involved multiple genes and no cases of SNVs in the NXF5 gene have been reported.Created: 1 Mar 2024, 4:15 p.m. | Last Modified: 1 Mar 2024, 4:15 p.m.
Panel Version: 5.483
Comment on publications: PMID: 23675524 was identified by the Genomics England Applied Machine Learning (ML) team in a Biocuration-ML project for identifying new gene-disease associations using Natural Language Processing (NLP) and Generative AI techniquesCreated: 1 Mar 2024, 4:12 p.m. | Last Modified: 1 Mar 2024, 4:12 p.m.
Panel Version: 5.482
- PMID: 11566096 (2001) and PMID: 12784308 (2003) - male patient with a pericentric inversion disrupting the NXF gene cluster on Xq22.1 - includes NXF5 which was shown to have reduced expression. Clinical characteristics include severe ID, short stature, pectus excavatum, muscle wasting, and facial dysmorphism
- PMID: 20096387 (2010) - female patient with severe ID, autism, micro-brachycephaly, generalised hypotonia with distal hypotrophy of lower limbs, scoliosis and facial dysmorphisms. Array-CGH analysis identified a 1.1 Mb deletion that contains part of the NXF gene cluster, harbouring the NXF5 gene. The deletion was inherited from her mother who presented with mild ID, short stature, brachycephaly, epilepsy and a Borderline Personality Disorder.
- PMID: 22030050 (2011) - female patient with a de novo duplication of Xq22.1, disrupting the NXF gene cluster which includes NXF5. Clinical features similar to other cases include ID, short stature, general muscle hypotonia, distal muscle hypotrophy of the lower extremities.
- PMID: 23675524 (2013) - mouse model evidence showing impairment in spatial learning and memory performance when the Nxf7 gene (suggested ortholog of human NXF5) is knocked outCreated: 1 Mar 2024, 4:09 p.m. | Last Modified: 1 Mar 2024, 4:09 p.m.
Panel Version: 5.480
Publications
Red List (low evidence)
Mode of inheritance
X-LINKED: hemizygous mutation in males, monoallelic mutations in females may cause disease (may be less severe, later onset than males)
Red List (low evidence)
Candidate gene in Targeted Next-Generation Sequencing Analysis of 1,000 Individuals with Intellectual Disability.Grozeva D et al., 2015 (PMID: 26350204 . Not enough evidence for direct nvolvement of NXF5 in ID, the gene is thought to be could be involved in development, possibly through a process in mRNA metabolism in neurons (PMID: 11566096)Created: 31 Oct 2017, 11:34 a.m.
Phenotypes
Intellectual Disability
Publications
Red List (low evidence)
Gene: nxf5 has been classified as Red List (Low Evidence).
Publications for gene: NXF5 were set to 11566096; 26350204; 23675524; 22030050; 20096387
Publications for gene: NXF5 were set to 11566096; 26350204; 23675524; 22030050
12.03.2018: Due to major updates completed (Phase 1, 2 and 3), this panel was promoted to Version 2 in order to reflect the major updates since November 2017 which have resulted in reviews for 836 genes added by Genomics England Curators and the Clinical Team, 130 new Green genes added to the interpretation pipeline (from 751 to 881 Green genes), and the gene total has increased from 1879 to 1927.
Publications for gene NXF5 was set to ['11566096', '26350204', ' 23675524', '22030050']
The Gel status was updated for this whole panel
The Gel status was updated for this whole panel
NXF5 was added to Intellectual disabilitypanel. Sources: Expert Review Red
NXF5 was created by ellenmcdonagh
If promoting or demoting a gene, please provide comments to justify a decision to move it.
Genes included in a Genomics England gene panel for a rare disease category (green list) should fit the criteria A-E outlined below.
These guidelines were developed as a combination of the ClinGen DEFINITIVE evidence for a causal role of the gene in the disease(a), and the Developmental Disorder Genotype-Phenotype (DDG2P) CONFIRMED DD Gene evidence level(b) (please see the original references provided below for full details). These help provide a guideline for expert reviewers when assessing whether a gene should be on the green or the red list of a panel.
A. There are plausible disease-causing mutations(i) within, affecting or encompassing an interpretable functional region(ii) of this gene identified in multiple (>3) unrelated cases/families with the phenotype(iii).
OR
B. There are plausible disease-causing mutations(i) within, affecting or encompassing cis-regulatory elements convincingly affecting the expression of a single gene identified in multiple (>3) unrelated cases/families with the phenotype(iii).
OR
C. As definitions A or B but in 2 or 3 unrelated cases/families with the phenotype, with the addition of convincing bioinformatic or functional evidence of causation e.g. known inborn error of metabolism with mutation in orthologous gene which is known to have the relevant deficient enzymatic activity in other species; existence of an animal model which recapitulates the human phenotype.
AND
D. Evidence indicates that disease-causing mutations follow a Mendelian pattern of causation appropriate for reporting in a diagnostic setting(iv).
AND
E. No convincing evidence exists or has emerged that contradicts the role of the gene in the specified phenotype.
(i)Plausible disease-causing mutations: Recurrent de novo mutations convincingly affecting gene function. Rare, fully-penetrant mutations - relevant genotype never, or very rarely, seen in controls. (ii) Interpretable functional region: ORF in protein coding genes miRNA stem or loop. (iii) Phenotype: the rare disease category, as described in the eligibility statement. (iv) Intermediate penetrance genes should not be included.
It’s assumed that loss-of-function variants in this gene can cause the disease/phenotype unless an exception to this rule is known. We would like to collect information regarding exceptions. An example exception is the PCSK9 gene, where loss-of-function variants are not relevant for a hypercholesterolemia phenotype as they are associated with increased LDL-cholesterol uptake via LDLR (PMID: 25911073).
If a curated set of known-pathogenic variants is available for this gene-phenotype, please contact us at [email protected]
We classify loss-of-function variants as those with the following Sequence Ontology (SO) terms:
Term descriptions can be found on the PanelApp homepage and Ensembl.
If you are submitting this evaluation on behalf of a clinical laboratory please indicate whether you report variants in this gene as part of your current diagnostic practice by checking the box
Standardised terms were used to represent the gene-disease mode of inheritance, and were mapped to commonly used terms from the different sources. Below each of the terms is described, along with the equivalent commonly-used terms.
A variant on one allele of this gene can cause the disease, and imprinting has not been implicated.
A variant on the paternally-inherited allele of this gene can cause the disease, if the alternate allele is imprinted (function muted).
A variant on the maternally-inherited allele of this gene can cause the disease, if the alternate allele is imprinted (function muted).
A variant on one allele of this gene can cause the disease. This is the default used for autosomal dominant mode of inheritance where no knowledge of the imprinting status of the gene required to cause the disease is known. Mapped to the following commonly used terms from different sources: autosomal dominant, dominant, AD, DOMINANT.
A variant on both alleles of this gene is required to cause the disease. Mapped to the following commonly used terms from different sources: autosomal recessive, recessive, AR, RECESSIVE.
The disease can be caused by a variant on one or both alleles of this gene. Mapped to the following commonly used terms from different sources: autosomal recessive or autosomal dominant, recessive or dominant, AR/AD, AD/AR, DOMINANT/RECESSIVE, RECESSIVE/DOMINANT.
A variant on one allele of this gene can cause the disease, however a variant on both alleles of this gene can result in a more severe form of the disease/phenotype.
A variant in this gene can cause the disease in males as they have one X-chromosome allele, whereas a variant on both X-chromosome alleles is required to cause the disease in females. Mapped to the following commonly used term from different sources: X-linked recessive.
A variant in this gene can cause the disease in males as they have one X-chromosome allele. A variant on one allele of this gene may also cause the disease in females, though the disease/phenotype may be less severe and may have a later-onset than is seen in males. X-linked inactivation and mosaicism in different tissues complicate whether a female presents with the disease, and can change over their lifetime. This term is the default setting used for X-linked genes, where it is not known definitately whether females require a variant on each allele of this gene in order to be affected. Mapped to the following commonly used terms from different sources: X-linked dominant, x-linked, X-LINKED, X-linked.
The gene is in the mitochondrial genome and variants within this can cause this disease, maternally inherited. Mapped to the following commonly used term from different sources: Mitochondrial.
Mapped to the following commonly used terms from different sources: Unknown, NA, information not provided.
For example, if the mode of inheritance is digenic, please indicate this in the comments and which other gene is involved.